LAVA Therapeutics NV held its annual general meeting of shareholders on June 11, 2025. During the meeting, several proposals were voted upon and approved. These included the adoption of the Dutch statutory annual accounts for the financial year 2024, the reappointment of James Noble and Jay Backstrom as non-executive directors, the extension of authorization for the board to acquire shares, the appointment of KPMG Accountants N.V. as the external auditor for 2025, and the ratification of KPMG LLP as the independent registered public accounting firm for the same year. Additionally, the release of board members from liability for the exercise of their duties during the financial year 2024 was approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.